文献速递肿瘤 PET/CT核素与放射性配体治疗

改良PROMISE标准用于胃泌素释放肽受体(GRPR)靶向PET的标准化解读

Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-08-09

研究回顾性分析本机构前瞻性研究中[68Ga]Ga-RM2 PET数据,包括44例分期和100例生化复发(BCR)前列腺癌患者,由两名核医学医师按改良PROMISE(mPROMISE)标准独立评估,第三名专家作为参考标准。结果显示mPROMISE标准在GRPR表达、前列腺床(T)、淋巴结(N)、骨骼(Mb)、器官(Mc)转移及最终判断上具有中等至几乎完美的一致性,与参考标准相比各亚组表现可接受。作者提出该改良标准有助于减少不确定性,并促进临床试验中GRPR靶向PET的统一评估、报告和可比性。

要点

  • mPROMISE标准在分期队列中GRPR表达的组间信度为中等(0.59;95%CI 0.40,0.78),T分期为实质性(0.78;95%CI 0.63,0.94)。
  • 分期队列中N分期和最终判断的组间信度几乎完美(分别为0.97;95%CI 0.92,1.00和0.92;95%CI 0.82,1.00)。
  • BCR队列中GRPR表达和最终判断的组间信度分别为实质性(0.70;95%CI 0.59,0.81)和(0.65;95%CI 0.53,0.78),主要类别(T、N、Mb、Mc)几乎完美。

核心结论

  • 使用mPROMISE标准解读GRPR靶向PET在所有主要类别中显示出实质性或几乎完美的组间信度。
  • 提出的PROMISE标准改良有助于临床医生减少不确定性,并有助于临床试验实现GRPR靶向PET的统一评估、报告和可比性。

研究设计与样本

  • 回顾性分析本机构前瞻性研究中[68Ga]Ga-RM2 PET数据,44例患者因分期成像,100例患者因生化复发前列腺癌成像。
  • 两名核医学医师按mPROMISE标准独立评估PET,第三名专家阅片者作为标准参考。
  • 计算GRPR表达、前列腺床(T)、淋巴结(N)、骨骼(Mb)、器官(Mc)转移及扫描最终判断的组间信度。

主要发现

  • 分期队列组间信度:GRPR表达为中等(0.59;95%CI 0.40,0.78),T分期为实质性(0.78;95%CI 0.63,0.94),N分期几乎完美(0.97;95%CI 0.92,1.00),最终判断几乎完美(0.92;95%CI 0.82,1.00)。
  • BCR队列组间信度:GRPR表达为实质性(0.70;95%CI 0.59,0.81),最终判断为实质性(0.65;95%CI 0.53,0.78),主要类别(T、N、Mb、Mc)几乎完美。
  • 与标准参考相比,mPROMISE标准在所有亚组中均显示可接受的表现。

关键数值与推荐

  • mPROMISE标准用于GRPR靶向PET解读,组间信度在分期队列GRPR表达为0.59(95%CI 0.40,0.78),T分期0.78(95%CI 0.63,0.94),N分期0.97(95%CI 0.92,1.00),最终判断0.92(95%CI 0.82,1.00)。
  • BCR队列GRPR表达组间信度0.70(95%CI 0.59,0.81),最终判断0.65(95%CI 0.53,0.78),主要类别(T、N、Mb、Mc)几乎完美。

临床怎么用

  • 作者认为使用mPROMISE标准解读GRPR靶向PET可减少临床医生不确定性,并促进临床试验中统一评估、报告和可比性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are image interpretation criteria to standardize reporting prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET). As up to 10% of prostate cancer (PC) do not express PSMA, other targets such as gastrin-releasing peptide receptor (GRPR) are evaluated. Research on GRPR-targeted imaging has been slowly increasing in usage at staging and biochemical recurrence (BCR) of PC. We therefore propose a modification of the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria (mPROMISE) for GRPR-targeted PET. METHODS: [68 Ga]Ga-RM2 PET data from initially prospective studies performed at our institution were retrospectively reviewed: 44 patients were imaged for staging and 100 patients for BCR PC. Two nuclear medicine physicians independently evaluated PET according to the mPROMISE criteria. A third expert reader served as standard reference. Interreader reliability was computed for GRPR expression, prostate bed (T), lymph node (N), skeleton (Mb), organ (Mc) metastases, and final judgment of the scan. RESULTS: The interrater reliability for GRPR PET at staging was moderate for GRPR expression (0.59; 95% confidence interval [CI] 0.40, 0.78), substantial for T-stage (0.78; 95% CI 0.63, 0.94), and almost perfect for N-stage (0.97; 95% CI 0.92, 1.00) and final judgment (0.92; 95% CI 0.82, 1.00). The interreader agreement at BCR showed substantial agreement for GRPR expression (0.70; 95% CI 0.59, 0.81) and final judgment (0.65; 95% CI 0.53, 0.78), while almost perfect agreement was seen across the major categories (T, N, Mb, Mc). Acceptable performance of the mPROMISE criteria was found for all subsets when compared to the standard reference. CONCLUSION: Interpreting GRPR-targeted PET using the mPROMISE criteria showed its reliability with substantial or almost perfect interrater agreement across all major categories. The proposed modification of the PROMISE criteria will aid clinicians in decreasing the level of uncertainty, and clinical trials to achieve uniform evaluation, reporting, and comparability of GRPR-targeted PET. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT03113617 and NCT02624518.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Duan H, Davidzon GA, Moradi F, et al. Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET. Eur J Nucl Med Mol Imaging. 2023. PMID: 37555901. doi:10.1007/s00259-023-06385-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。